ApniWave accurately and cost-efficiently screens Obstructive Sleep Apnea – Hypopnea Syndrome (OSAHS) patients at home.
OSAHS often remains undiagnosed and consists an increased risk factor for individuals and the society as a whole. The gold standard in OSAHS diagnosis is polysomnography but it is an expensive and resource-intensive procedure. Current at-home screening solutions rely on pulse rate and oximetry measurements, thus only indirectly assessing apnea; they are also too obtrusive or too inaccurate to be used.
ApniWave is a totally unobtrusive device that directly assesses apnea by breath tracking using state-of-the-art hardware and employing advanced machine learning models tailored to measure apneic indexes.
1 July 2022